Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2000-10-3
pubmed:abstractText
B-Chronic lymphocytic leukemia (B-CLL) is an example of a human malignancy caused by alterations in the pathways of programmed cell death. In this disease the anti-apoptotic protein, bcl-2, is overexpressed and may lead to the prolonged survival of a malignant CLL clone. In the present study we examined the expression of bcl-2 and bax, which has an antagonistic role against the function of bcl-2, in cells from CLL patients at different stages of the disease, by immunoblot analysis. A direct association between the stage of the disease and the level of bcl-2 in the patients' cells was observed. At stages A and B, 33% and 29% of patients, respectively, expressed high levels of bcl-2, as opposed to 80% of patients at stage C (p= 0.019). Bax level was not significantly associated with the stage of the disease, although patients at stage C had higher levels of bax. In this study we found a trend of association between bcl-2 and bax levels. Analysis including all patients revealed that 65% of the patients who expressed high levels of bcl-2 had high levels of bax (p = 0.058). Of patients in stage C, 45% expressed high levels of both bcl-2 and bax while 50% and 42% of patients at stages A and B had low levels of both proteins.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0902-4441
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
80-4
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease.
pubmed:affiliation
Division of Haematology, Rabin Medical Center, Petach-Tikva, Israel. aviramar@netvision.net.il
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't